Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial

Anita J. W. M. Brouns, Lizza E. L. Hendriks, Vincent van Der Noort, Ben E. E. M. van de Borne, Franz M. N. H. Schramel, Harry J. M. Groen, Bonne Biesma, Hans J. M. Smit, Anne-Marie C. Dingemans*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Web of Science)

Abstract

Introduction:Approximately 80% of non-small cell lung cancer (NSCLC) patients with bone metastases have cancer induced bone pain (CIBP). Methods:The NVALT-9 was an open-label, single arm, phase II, multicenter study. Main inclusion criterion: bone metastasized NSCLC patients with uncontrolled CIBP [brief pain inventory [BPI] >= 5 over last 7 days]. Patients were treated with six milligram ibandronate intravenously (day 1-3) once a day. Main exclusion criteria: active secondary malignancy, systemic anti-tumor treatment and radiotherapy = 80% and 95% confidence to declare the treatment inactive if the pain response rate is

Original languageEnglish
Article number890
Number of pages5
JournalFrontiers in Oncology
Volume10
DOIs
Publication statusPublished - 24 Jun 2020

Keywords

  • carcinoma
  • non-small-cell lung
  • pain management
  • cancer induced bone pain
  • clinical trials
  • phase II as topic
  • ibandronic acid
  • QUALITY-OF-LIFE
  • SKELETAL METASTASES
  • BISPHOSPHONATES
  • DISEASE

Cite this